![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
By Stephen Nakrosis
The shares of several companies pursuing treatments for Alzheimer's Disease got a boost on Wednesday, after Eisai Co. Ltd. and Biogen Inc. said a study of their lecanemab showed highly statistically significant reduction of clinical decline in early Alzheimer's Disease.
Eisai said it plans to discuss the data with regulatory authorities in the U.S., Japan and Europe. The company also said it aims to file for traditional approval in the U.S. and for marketing authorization applications in Japan and Europe by March 31, 2023.
Shares of Acumen Pharmaceuticals Inc. had nearly doubled at midday, trading about 97% higher, at $9.26 a share. Volume at the time topped 45.2 million shares, above the stock's 65-day average volume of just over 61,000 shares.
Shares of Prothena Corp. PLC were trading around 72% higher, at $53.14 a share. Volume at the time was over 7.1 million shares. The stock's 65-day average volume is 373,989 shares.
Denali Therapeutics Inc. shares were up nearly 21% higher, at $33.01 a share. Volume at the time topped 1.3 million shares, above the stock's 65-day average volume of 617,185 shares.
Shares of Biogen were up more than 37%, at $270.97 a share. Volume topped 11.7 million shares, above the 65-day average volume of 907,162 shares.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2022 13:30 ET (17:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions